Morepen Labs net profit leaps over 6 fold to Rs 27crore in Q2

Published On 2020-11-11 06:35 GMT   |   Update On 2020-11-11 06:35 GMT
Advertisement

New Delhi: Drug firm Dr Morepen Laboratories on Monday reported an over six-fold jump in its consolidated net profit to Rs 27.16 crore for the quarter ended September, on account of robust sales. The company had posted a net profit of Rs 4.08 crore for the corresponding period of the previous fiscal, Morepen Labs said in a BSE filing.

Total revenue stood at Rs 340.12 crore for the quarter under consideration. It was Rs 216.24 crore for the same period a year ago, it added.
Advertisement
"Company is investing heavily to build strong pipeline of products to be launched in three to four years. This investment would go both in R&D and in building new product blocks to create extra production capacities," Morepen Laboratories Chairman and MD Sushil Suri said.
The focus of the company continues to remain on the chronic and lifestyle diseases, he added.

Read also: Morepen Labs net profit leaps over two-fold to Rs 19.36 crore in Q1



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News